Enzyme replacement and enhancement therapies: lessons from lysosomal disorders (Q35013195)

5 August 2017

1 reference

title

Enzyme replacement and enhancement therapies: lessons from lysosomal disorders (English)

1 reference

5 August 2017

1

Robert J Desnick

1 reference

5 August 2017

2

Edward H Schuchman

1 reference

5 August 2017

1 December 2002

1 reference

5 August 2017

Nature Reviews Genetics

1 reference

5 August 2017

3

1 reference

5 August 2017

954-966

1 reference

5 August 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/nrg963

5 August 2017

0 references

cites work

Prevalence of lysosomal storage disorders

1 reference

The biogenesis of lysosomes

31 March 2020

1 reference

A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes

31 March 2020

1 reference

Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts

31 March 2020

1 reference

Characterization of a membrane-associated receptor from bovine liver that binds phosphomannosyl residues of bovine testicular beta-galactosidase

31 March 2020

1 reference

Lysosomal enzyme targeting

31 March 2020

1 reference

Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes

31 March 2020

1 reference

Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors

31 March 2020

1 reference

Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy

31 March 2020

1 reference

Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier

31 March 2020

1 reference

Correction of Abnormal Cerebroside Sulfate Metabolism in Cultured Metachromatic Leukodystrophy Fibroblasts

31 March 2020

1 reference

Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts

31 March 2020

1 reference

Sandhoff disease: defective glycosaminoglycan catabolism in cultured fibroblasts and its correction by beta-N-acetylhexosaminidase

31 March 2020

1 reference

Replacement Therapy for Inherited Enzyme Deficiency

31 March 2020

1 reference

Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes

31 March 2020

1 reference

Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.

31 March 2020

1 reference

Enzyme replacement in Tay-Sachs disease

31 March 2020

1 reference

Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin

31 March 2020

1 reference

Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease

31 March 2020

1 reference

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

31 March 2020

1 reference

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

31 March 2020

1 reference

Enzyme therapy for Gaucher disease: the first 5 years.

31 March 2020

1 reference

Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion

31 March 2020

1 reference

Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II

31 March 2020

1 reference

Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology

31 March 2020

1 reference

Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice

31 March 2020

1 reference

Implantation of genetically engineered fibroblasts into mice: implications for gene therapy

31 March 2020

1 reference

Bioproduction of human enzymes in transgenic tobacco

31 March 2020

1 reference

Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism

31 March 2020

1 reference

New therapeutic prospects for the glycosphingolipid lysosomal storage diseases.

31 March 2020

1 reference

alpha-Galactosidase A deficient mice: a model of Fabry disease

31 March 2020

1 reference

Mouse models of Niemann-Pick disease: mutation analysis and chromosomal mapping rule out the type A and B forms

31 March 2020

1 reference

Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease).

31 March 2020

1 reference

Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy

31 March 2020

1 reference

Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene

31 March 2020

1 reference

Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase

31 March 2020

1 reference

Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI

31 March 2020

1 reference

Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease

31 March 2020

1 reference

Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II

31 March 2020

1 reference

Enzyme therapy for lysosomal acid lipase deficiency in the mouse

31 March 2020

1 reference

A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome).

31 March 2020

1 reference

Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene

31 March 2020

1 reference

Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene

31 March 2020

1 reference

An inducible mouse model of late onset Tay-Sachs disease.

31 March 2020

1 reference

Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer

31 March 2020

1 reference

Specificity of mouse GM2 activator protein and beta-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2

31 March 2020

1 reference

Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

31 March 2020

1 reference

Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor

31 March 2020

1 reference

Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and c

31 March 2020

1 reference

The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.

31 March 2020

1 reference

Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb.

31 March 2020

1 reference

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

31 March 2020

1 reference

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

31 March 2020

1 reference

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

31 March 2020

1 reference

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

31 March 2020

1 reference

Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk

31 March 2020

1 reference

Enzyme-replacement therapy in mucopolysaccharidosis I.

31 March 2020

1 reference

Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy.

31 March 2020

1 reference

Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII.

31 March 2020

1 reference

Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease

31 March 2020

1 reference

ER-associated degradation in protein quality control and cellular regulation

31 March 2020

1 reference

Identification of the cystic fibrosis gene: genetic analysis

31 March 2020

1 reference

Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation.

31 March 2020

1 reference

Alpha1-antitrypsin deficiency--a model for conformational diseases

31 March 2020

1 reference

Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators

31 March 2020

1 reference

Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency

31 March 2020

1 reference

Influence of molecular and chemical chaperones on protein folding

31 March 2020

1 reference

Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein

31 March 2020

1 reference

In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.

31 March 2020

1 reference

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants

31 March 2020

1 reference

Toxic proteins in neurodegenerative disease

31 March 2020

1 reference

Antagonists to the rescue

31 March 2020

1 reference

Pharmacological chaperones: a new twist on receptor folding.

31 March 2020

1 reference

Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease

31 March 2020

1 reference

In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives

31 March 2020

1 reference

Toward enzyme therapy for lysosomal storage diseases

31 March 2020

1 reference

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRG963

1 reference

PubMed ID

12459725

Dimensions Publication ID

5 August 2017

0 references

1 reference

PubMed ID

12459725